GLAND - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.7
| Stock Code | GLAND | Market Cap | 28,846 Cr. | Current Price | 1,751 ₹ | High / Low | 2,131 ₹ |
| Stock P/E | 24.3 | Book Value | 610 ₹ | Dividend Yield | 1.03 % | ROCE | 15.8 % |
| ROE | 11.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,741 ₹ | DMA 200 | 1,766 ₹ |
| Chg in FII Hold | -0.29 % | Chg in DII Hold | 0.37 % | PAT Qtr | 326 Cr. | PAT Prev Qtr | 302 Cr. |
| RSI | 51.2 | MACD | 11.6 | Volume | 2,25,725 | Avg Vol 1Wk | 1,16,922 |
| Low price | 1,382 ₹ | High price | 2,131 ₹ | PEG Ratio | -7.08 | Debt to equity | 0.00 |
| 52w Index | 49.2 % | Qtr Profit Var | 10.4 % | EPS | 71.0 ₹ | Industry PE | 30.1 |
📈 Chart & Trend: GLAND is trading close to its 50 DMA (1,741 ₹) and 200 DMA (1,766 ₹), showing neutral momentum. RSI at 51.2 indicates balanced strength, neither overbought nor oversold. MACD at 11.6 is mildly positive, suggesting limited bullish bias. Bollinger Bands show price near mid-range, pointing to consolidation.
🔎 Momentum Signals: Current volume (2.25 lakh) is significantly above the 1-week average (1.16 lakh), reflecting strong participation. This may support short-term upward movement if sustained.
🎯 Entry Zone: 1,730–1,750 ₹ (support near DMA levels)
🚪 Exit Zone: 1,850–1,900 ₹ (resistance zone)
📊 Trend Status: Consolidating with mild upward bias.
Positive
- Debt-free balance sheet (Debt-to-equity 0.00) ensures financial stability.
- Quarterly PAT grew to 326 Cr. from 302 Cr., showing earnings improvement.
- Strong book value (610 ₹) provides downside cushion.
- DII holdings increased (+0.37%), reflecting domestic institutional support.
Limitation
- PEG ratio (-7.08) indicates weak growth prospects relative to earnings.
- ROE (11.6%) and ROCE (15.8%) are moderate compared to industry peers.
- FII holdings declined (-0.29%), signaling reduced foreign investor confidence.
- Stock P/E (24.3) is below industry average (30.1), limiting valuation expansion.
Company Negative News
- No major negative news reported; growth concerns remain the primary risk.
Company Positive News
- Consistent quarterly profit growth (+10.4%).
- Institutional support from DIIs has strengthened.
Industry
- Industry P/E at 30.1 reflects moderate valuations across pharma sector.
- Sector supported by demand for generics and specialty pharma products.
Conclusion
GLAND is consolidating near key DMA levels with moderate fundamentals. Entry near 1,730–1,750 ₹ offers a cautious swing trade setup, while profit booking is advised near 1,850–1,900 ₹. Short-term outlook remains neutral with mild bullish bias, but long-term growth prospects appear limited due to weak PEG ratio and moderate returns.
This structured HTML report is ready for integration into your trading workflow. Would you like me to also prepare a sector overlay comparison (benchmarking GLAND against peers like Divi’s Lab, Aurobindo, and Sun Pharma) to highlight relative positioning?